St. Jude Medical recommended ahead of HRS meeting at JPMorgan JPMorgan recommends buying shares of St. Jude Medical ahead of next week's Heart Rhythm Society meeting. The firm expects the meeting to ease concerns surrounding Durata and it sees the potential for a CardioMEMS approval going into the meeting. JPMorgan reiterates an Overweight rating on St. Jude with a $74 price target.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.